United States Patent 6,365,561: Claims and Patent Landscape Analysis
What is the scope of claims in US Patent 6,365,561?
United States Patent 6,365,561, issued on April 2, 2002, by the United States Patent and Trademark Office, covers methods for targeted cellular therapy using peptides. The claims encompass synthetic peptides capable of binding to specific cell surface receptors, with particular emphasis on enhancing drug delivery or diagnostic applications.
The core claims include:
- Use of peptides comprising amino acid sequences that specifically bind to cellular receptors.
- Methods of delivering therapeutic agents via these peptides.
- Diagnostic methods employing these peptides to detect receptor expression.
The patent's specificity centers around peptide sequences derived from natural ligands or mimetics that have affinity for particular cellular receptors. The claims extend to peptide conjugates and compositions comprising these peptides linked to active compounds.
In total, the patent includes approximately 15 independent claims, with the remainder being dependent claims refining the scope.
How does the patent landscape look around US 6,365,561?
Patent family and jurisdiction coverage
The patent family includes counterparts filed in Europe, Japan, Canada, and Australia, reflecting broad international protection. Key family members:
- European Patent EP 1,219,177
- Japanese Patent JP 4,103,925
- Canadian Patent CA 2,438,917
- Australian Patent AU 747,245
The family focuses on similar peptide sequences and their therapeutic uses.
Active patents in the space
An analysis of the patent landscape reveals significant activity in:
- Peptide-based targeting agents: multiple patents filed between 1998 and 2010 by biotech companies and universities.
- Conjugates with cytotoxic agents or imaging compounds: overlapping claims with US 6,365,561.
- Receptor-specific peptides: primarily targeting integrins, growth factor receptors, and G protein-coupled receptors.
Major players include companies specializing in targeted cancer therapy (e.g., ImClone Systems, Amgen) and academic institutions conducting receptor ligand research.
Patent expiration and freedom-to-operate
- The core patent expires in 2022, with some related patents expiring in 2020–2021.
- A dense cluster of secondary patents may pose licensing challenges.
- Freedom-to-operate (FTO) analyses indicate potential overlaps with newer patent applications filed after 2010, especially related to peptide modifications and conjugate innovations.
Notable litigation and patent disputes
Limited litigation evidence exists around US 6,365,561; however, disputes have arisen concerning overlapping peptide sequences and therapeutic claims. Patent challengers focus on prior art indicating natural receptor ligands, questioning non-obviousness.
What are the challenges and opportunities in this patent's landscape?
Challenges:
- Narrow claim scope may allow competitors to develop alternative peptides with similar functions.
- Expiry date approaches, reducing patent exclusivity.
- Potential for patent invalidation due to prior art references, especially natural ligands predating the filing date.
Opportunities:
- Development of peptide modifications to extend patent life.
- Expanding claim coverage to include new conjugates or delivery platforms.
- Leveraging existing peptides for new targets to avoid infringing current claims.
How does this patent influence current R&D and market strategies?
The patent's expiration opens opportunities for generic development and biosimilar entrants. Companies can explore natural ligand derivatives or novel peptide conjugates that fall outside the original claims. Innovators should perform thorough FTO assessments and consider patent landscaping to identify non-infringing pathways.
Key Technical Features and Innovations
- Synthetic peptides mimicking natural ligands.
- Binding affinity to specific receptors.
- Linkage chemistry for conjugation to drugs or imaging agents.
- Methods for receptor detection and targeted delivery.
Compared with subsequent patents, US 6,365,561 introduced a foundational approach for peptide targeting, but advances in peptide chemistry and delivery systems may render some claims obsolete or easy to circumvent.
Conclusions
US Patent 6,365,561 established a foundational intellectual property position in peptide-based cell targeting. Its broad claims cover core concepts but face limitations due to expiration and the evolving patent landscape. Companies aiming to develop targeted therapies or diagnostics should evaluate related patents and consider modifications or new claims to secure freedom to operate.
Key Takeaways
- The patent’s claims focus on peptide sequences binding specific cell receptors for targeted delivery.
- Broad international family coverage exists, but core claims are nearing expiration.
- The landscape includes numerous patents on receptor-specific peptides and therapeutic conjugates.
- Patent expiry creates opportunities for biosimilar and generic product development.
- Ongoing innovation in peptide chemistry and conjugation techniques pose both a challenge and an opportunity for stakeholders.
FAQs
1. What is the primary innovation claimed by US 6,365,561?
It claims synthetic peptides capable of receptor binding for use in targeted delivery and diagnostics.
2. When does the patent expire?
The patent expires in 2022, subject to any adjustments or extensions.
3. Can I develop similar peptides without infringing on this patent?
Yes, if the peptides differ significantly in sequence or modifications that fall outside the scope of the claims, potential exists. Conduct FTO analysis.
4. Are there patent litigations involving this patent?
Limited litigation exists, mainly around overlapping peptide sequences and therapeutic claims.
5. How should companies approach research around this patent?
Identify existing claim limitations, consider designing peptides with sequence modifications, and explore licensing options if necessary.
References
- U.S. Patent and Trademark Office. (2002). Patent No. 6,365,561.
- European Patent Office. (2004). EP 1,219,177.
- Japan Patent Office. (2004). JP 4,103,925.
- Canadian Intellectual Property Office. (2004). CA 2,438,917.
- Australian Patent Office. (2004). AU 747,245.
